Inhaled capsaicin (CAP)
Phase 2Small molecule
Inhaled capsaicin (CAP) is one of 13 small molecule programs targeting Chronic Cough. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Chronic Cough
#DrugCompanyPhaseTrials
1Singulair
OOrganon and Co
Approved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Nucala
GGlaxo Dba Glaxosmithkline
Approved
Nexium
DDexcel Pharma Technologies Ltd.
Approved
Aspercreme Warming
AAveritas Pharma, Inc.
Approved
Quietus
Merck & Co.Phase 3
Pulmicort
SSalix
Preclinical
NOC-110
NNocion Therapeutics
Phase 2
Inhaled capsaicin (CAP)
UUniversity of Montana
Phase 2
HS-10383
Jiangsu Hansoh Pharmaceutical Co., Ltd.Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Inhaled capsaicin (CAP). EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity of Montana